Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | USP10 | Q14694 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GALR2 | O43603 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377153 | 0.91 | ALDH1A1 (0.38) | ALDH1A1TDP1TSHRKMT2AMEN1 | |
| SCHEMBL377154 | 0.91 | ALDH1A1 (0.38) | ALDH1A1TDP1TSHRKMT2AMEN1 | |
| SCHEMBL28413275 | 0.87 | ALDH1A1 (0.41) | ALDH1A1TDP1TSHRKMT2AMEN1 | |
| SCHEMBL28556720 | 0.84 | MAPT (0.40) | ALDH1A1TDP1TSHRKMT2AMEN1 | |
| SCHEMBL2974511 | 0.80 | ALDH1A1 (0.40) | ALDH1A1TDP1TSHRKMT2AMEN1 | |
| SCHEMBL769470 | 0.79 | ALDH1A1 (0.38) | ALDH1A1TDP1TSHRKMT2AMEN1 | |
| SCHEMBL28539173 | 0.78 | ALDH1A1 (0.39) | ALDH1A1TDP1TSHRKMT2AMEN1 | |
| SCHEMBL27869482 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TDP1TSHRKMT2AMEN1 | |
| SCHEMBL28556722 | 0.75 | MAPT (0.39) | ALDH1A1TDP1TSHRKMT2AMEN1 | |
| SCHEMBL376867 | 0.73 | SMN1; SMN2 (0.47) | ALDH1A1TDP1TSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3330255-B1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3330255-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2408749-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20170327456-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-11-16 | — | — | US | disclosed |
| EP-2821400-B1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9751839-B2 | Process for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170096396-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-06 | — | — | US | disclosed |
| US-20160221952-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-04 | — | — | US | disclosed |
| US-9371287-B2 | Process for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150315151-A2 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-05 | — | — | US | disclosed |
| US-8614325-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-24 | — | — | US | disclosed |
| US-8476442-B2 | Process for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130072522-A1 | Process for Making Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120122921-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120071504-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2408750-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2408749-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20100267768-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-21 | — | — | US | disclosed |
| WO-2010108155-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010108162-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327456-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | ALDH1A1 948/4885TDP1 4850/4885TSHR 2315/4885 |
| US-20130072522-A1 | Process for Making Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SLC26A4, TMEM109 | ALDH1A1 948/4885TDP1 4850/4885TSHR 2315/4885 |
| US-20100267768-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | ALDH1A1 948/4885TDP1 4850/4885TSHR 2315/4885 |
| US-20170096396-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | ALDH1A1 948/4885TDP1 4850/4885TSHR 2315/4885 |
| US-20120122921-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | ALDH1A1 948/4885TDP1 4850/4885TSHR 2315/4885 |
| US-20160221952-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, CLCN2 | ALDH1A1 2280/4885TDP1 4869/4885TSHR 1197/4885 |
| US-20150315151-A2 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | ALDH1A1 948/4885TDP1 4850/4885TSHR 2315/4885 |
| US-20120071504-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, CLCN2 | ALDH1A1 2280/4885TDP1 4869/4885TSHR 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.